Publications, Pharmaceutical

Aptar Pharma Q&A on trends and challenges in nasal drug delivery

Nasal drug delivery is currently the focus of considerable drug development activity.

This Q&A takes a detailed look at the nasal drug delivery landscape and the potential of this route for the delivery of vaccines and therapeutics for COVID-19, for nose-to-brain drug delivery and for improving the accessibility of emergency medications. Key challenges associated with the development of nasal drug products are outlined along with factors impacting device design and selection.
The regulatory landscape is also considered. Barriers to the development of nasal drug delivery products are examined but it is concluded that the route has a bright future with considerable potential to address currently unmet therapeutic needs.

Download the Q&A
Author(s): Dr Julie D. Suman
21 Apr 2022

Learn more about Aptar Pharma Expertise
in Nasal Drug Delivery

Find Out More

This Might Also Be of Interest

1 Apr 2020

Demonstrating bioequivalence in generic orally inhaled drug products

Publications, Pharmaceutical, Innovation & Insights

Read More
1 Apr 2020

Patient training and onboarding for intranasal rescue treatments

Publications, Pharmaceutical, Product Solutions, Innovation & Insights, Device Innovations

Read More
1 Dec 2019

The Current State of Play in Connected Devices

Publications, Pharmaceutical, Innovation & Insights, Device Innovations, Brand Differentiation, Product Solutions

Read More
1 Nov 2019

Exploring a Faster, More Cost-Effective Alternative to Generic Bioequivalence

Publications, Pharmaceutical, Innovation & Insights, Product Solutions

Read More
1 … 22 23 24 25 26 27

Request Access

Close

Requesting access to Aptar Pharma Q&A on trends and challenges in nasal drug delivery.

  • This field is for validation purposes and should be left unchanged.

How Can We Help?

Back To Top